Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2.

The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are d...
770KB Sizes 1 Downloads 0 Views

Recommend Documents

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia.
To evaluate the effectiveness of intravitreal bevacizumab (IVB) in patients with subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.

Short-term effects of intravitreal bevacizumab in type ii idiopathic macular telangiectasia.
To report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).

Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab.
We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema wa

Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex).
A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye. Visual symptoms were refractory to initial treatment with intravitreal

[Functional characteristics of macular telangiectasia type 2].
The first symptoms of macular telangiectasia type 2 usually occur between 50 and 70 years of age. Functional alterations topographically correspond to the morphological changes. Characteristic paracentral scotomata due to focal photoreceptor atrophy

Macular telangiectasia type 2 (MacTel) in a 34-year-old patient.
We report macular telangiectasia type 2 (MacTel) in a 34-year-old man, the youngest patient so far published with MacTel type 2. The patient presented with metamorphopsia and impaired reading ability. Diagnosis was based on bilateral abnormal macular

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol.
To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially trea

The purpose of this study is to determine whether bevacizumab is detectable in the breast milk of nursing mothers.